These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27756458)

  • 1. Lessons Learned From Developing an Eradication Investment Case for Lymphatic Filariasis.
    Kastner RJ; Stone CM; Steinmann P; Tanner M; Tediosi F
    Adv Parasitol; 2016; 94():393-417. PubMed ID: 27756458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How much will it cost to eradicate lymphatic filariasis? An analysis of the financial and economic costs of intensified efforts against lymphatic filariasis.
    Kastner RJ; Sicuri E; Stone CM; Matwale G; Onapa A; Tediosi F
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005934. PubMed ID: 28949987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling lymphatic filariasis transmission and control: modelling frameworks, lessons learned and future directions.
    Stolk WA; Stone C; de Vlas SJ
    Adv Parasitol; 2015 Mar; 87():249-91. PubMed ID: 25765197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame.
    Rebollo MP; Bockarie MJ
    Expert Rev Anti Infect Ther; 2013 Jul; 11(7):723-31. PubMed ID: 23879610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination of lymphatic filariasis in west African urban areas: is implementation of mass drug administration necessary?
    Koudou BG; de Souza DK; Biritwum NK; Bougma R; Aboulaye M; Elhassan E; Bush S; Molyneux DH
    Lancet Infect Dis; 2018 Jun; 18(6):e214-e220. PubMed ID: 29402636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneous dynamics, robustness/fragility trade-offs, and the eradication of the macroparasitic disease, lymphatic filariasis.
    Michael E; Singh BK
    BMC Med; 2016 Jan; 14():14. PubMed ID: 26822124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs.
    Kastner RJ; Stone CM; Steinmann P; Tanner M; Tediosi F
    PLoS Negl Trop Dis; 2015; 9(10):e0004147. PubMed ID: 26451729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global programme to eliminate lymphatic filariasis: progress report, 2015.
    Wkly Epidemiol Rec; 2016 Sep; 91(39):441-55. PubMed ID: 27758091
    [No Abstract]   [Full Text] [Related]  

  • 9. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007).
    Chu BK; Hooper PJ; Bradley MH; McFarland DA; Ottesen EA
    PLoS Negl Trop Dis; 2010 Jun; 4(6):e708. PubMed ID: 20532228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical modelling and the control of lymphatic filariasis.
    Michael E; Malecela-Lazaro MN; Simonsen PE; Pedersen EM; Barker G; Kumar A; Kazura JW
    Lancet Infect Dis; 2004 Apr; 4(4):223-34. PubMed ID: 15050941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass drug administration to eliminate lymphatic filariasis in India.
    Ramaiah KD; Das PK
    Trends Parasitol; 2004 Nov; 20(11):499-502. PubMed ID: 15471698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000-2014).
    Turner HC; Bettis AA; Chu BK; McFarland DA; Hooper PJ; Ottesen EA; Bradley MH
    Infect Dis Poverty; 2016 May; 5(1):54. PubMed ID: 27388873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geographic and ecologic heterogeneity in elimination thresholds for the major vector-borne helminthic disease, lymphatic filariasis.
    Gambhir M; Bockarie M; Tisch D; Kazura J; Remais J; Spear R; Michael E
    BMC Biol; 2010 Mar; 8():22. PubMed ID: 20236528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onchocerciasis and lymphatic filariasis elimination in Africa: it's about time.
    Evans DS; Unnasch TR; Richards FO
    Lancet; 2015 May; 385(9983):2151-2. PubMed ID: 26068266
    [No Abstract]   [Full Text] [Related]  

  • 15. Towards elimination of lymphatic filariasis: social mobilization issues and challenges in mass drug administration with anti-filarial drugs in Tamil Nadu, South India.
    Nandha B; Krishnamoorthy K; Jambulingam P
    Health Educ Res; 2013 Aug; 28(4):591-8. PubMed ID: 23503571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphatic filariasis: Treatment, control and elimination.
    Ottesen EA
    Adv Parasitol; 2006; 61():395-441. PubMed ID: 16735170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of mass drug administration on elimination of lymphatic filariasis in Surat city, India.
    Vaishnav KG; Desai HS; Srivastava PK; Joshi PT; Kurian G; Thakor HG; Dhariwal AC
    J Commun Dis; 2012 Dec; 44(4):251-9. PubMed ID: 25145075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can Lymphatic Filariasis Be Eliminated by 2020?
    Rebollo MP; Bockarie MJ
    Trends Parasitol; 2017 Feb; 33(2):83-92. PubMed ID: 27765440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investing in justice: ethics, evidence, and the eradication investment cases for lymphatic filariasis and onchocerciasis.
    Bailey TC; Merritt MW; Tediosi F
    Am J Public Health; 2015 Apr; 105(4):629-36. PubMed ID: 25713967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current practices in the management of lymphatic filariasis.
    Bockarie MJ; Taylor MJ; Gyapong JO
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):595-605. PubMed ID: 19485799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.